KR940005295A - 부위- 지향성 치료방법 및 치료수단 - Google Patents

부위- 지향성 치료방법 및 치료수단 Download PDF

Info

Publication number
KR940005295A
KR940005295A KR1019930014146A KR930014146A KR940005295A KR 940005295 A KR940005295 A KR 940005295A KR 1019930014146 A KR1019930014146 A KR 1019930014146A KR 930014146 A KR930014146 A KR 930014146A KR 940005295 A KR940005295 A KR 940005295A
Authority
KR
South Korea
Prior art keywords
targeting component
decay time
radioisotope
fragment
medium
Prior art date
Application number
KR1019930014146A
Other languages
English (en)
Other versions
KR100304155B1 (ko
Inventor
윌렘 기어링스 마우리츠
Original Assignee
에프.지.엠.헤르만스, 에이. 지.제이.베르미렌
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠.헤르만스, 에이. 지.제이.베르미렌, 악조 엔.브이. filed Critical 에프.지.엠.헤르만스, 에이. 지.제이.베르미렌
Publication of KR940005295A publication Critical patent/KR940005295A/ko
Application granted granted Critical
Publication of KR100304155B1 publication Critical patent/KR100304155B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Electrotherapy Devices (AREA)
  • Tents Or Canopies (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Massaging Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 부위지향성 치료법 분야에 관한 것이다. 더욱 구체적으로 부위지향성 방사능요법에 관한 것이다.
본 발명은 방사능면역요법을 위한 방사능면역 결합체의 제조방법과 장치를 제공한다. 이 방법, 결합체 및 장치는 방사능차단장비 및/또는 기밀장비(airtight facilities)가 없는 상태에서 실시 할 수 있다. 상술한 제한적인 요인 없이 본 발명은 환자의 근접위치에서 간단하고 효과적인 치료수단을 제공한다.

Description

부위-지향성 치료방법및 치료수단
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명에 따른 장치를 도시한 것이다.
제2도는225Ac의 붕괴사슬을 도시한 것이다,
제3도는 본 발명에 의한 다른 장치를 도시한 것이다,
제4도는 여러가지 농도의 HCl과 HT에서 얻어진213Bi의 용출특성을 나타낸 것이다.

Claims (12)

  1. 환자의 근접위치에서 적어도 일종의 방사능동위원소와 표적화 성분으로 구성된 결합체를 제조하는 방법으로서, 붕괴서열내의 딸분자들이 주로 α선 및/또는 β선을 방출하는 비교적 긴 붕괴시간을 지닌 방사능동위원소를 적절한 매체상에 로오딩하고 이 배지 밖으로 비교적 짧은 붕괴시간을 지닌 동위원소를 용출시켜 표적화성분에 결합시키는 것을 특징으로 하는 방법.
  2. 제1항에 있어서, 상기 긴 붕괴시간을 지닌 동위원소는225Ac이고, 상기 비교적 짧은 붕괴시간을 지닌 동위원소는213Bi인 것을 특징으로 하는 방법.
  3. 제1항 또는 제2항에 있어서, 상기 표적화 성분은 모노클론 항체, 또는 그의 단편 또는 유도체 인것을 특징으로 하는 방법.
  4. 제1항 내지 제3항중 어느 한항에 있어서, 상기 표적화 성분은 인체 또는 인체화된 항체 또는 그의 단편 또는 유도체 인것을 특징으로 하는 방법.
  5. 제3항 또는 제4항에 있어서, 상기 모노클론 항체는 종양 관련항원에 대해 지향성이 있는 것임을 특징으로 하는 방법.
  6. 제1항 또는 제2항에 있어서, 상기 표적화 성분은 세포표면 수용체에 대한 리간드 또는 이 리간드의 단편 또는 유도체 인것을 특징으로 하는 방법.
  7. 전술한 항들중 어는 한항에 있어서, 상기 표적화 성분들에 캐리어를 결합시키며, 이렇게 함으로써 가장 적절한 매체밖에서 이 캐리어에 방사능 동위원소를 로오딩시키는 것을 특징으로 하는 방법.
  8. 전술한 항들중 어는 한항에의한 방법으로 제조되는 것을 특징으로 하는, 표적화 성분과 방사능 동위원소로 구성된 결합체.
  9. 제8항에 의한 결합제와 적절한 주사용 용액을 포함하는 것을 특징으로 하는 약학적 제제.
  10. 비교적 붕괴시간이 긴 동위원소와 적절한 중합체를 함유하는 이온교환컬럼을 포함하는 것을 특징으로 하는 부위 지향성 방사능요법용 장치.
  11. 제10항에 있어서, 적절한 매체내로 표적화성분을 포함하는 용액을 도입시키기 위한 수단을 포함하는 것을 특징으로 하는 장치.
  12. 제11항에 있어서, 상기 결합제를 주사용액과 함께 투여하기 위한 수단을 포함하는 것을 특징으로 하는 장치.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930014146A 1992-07-27 1993-07-26 표적화성분과비스무스방사성동위원소의결합체,그의제조방법및그를사용한치료방법 KR100304155B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP93.200.388.2 1992-02-11
EP92202301 1992-07-27
EP92.202.301.5 1992-07-27
EP93200388 1993-02-11

Publications (2)

Publication Number Publication Date
KR940005295A true KR940005295A (ko) 1994-03-21
KR100304155B1 KR100304155B1 (ko) 2001-11-22

Family

ID=26131590

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930014146A KR100304155B1 (ko) 1992-07-27 1993-07-26 표적화성분과비스무스방사성동위원소의결합체,그의제조방법및그를사용한치료방법

Country Status (15)

Country Link
US (2) US5641471C1 (ko)
EP (1) EP0585986B1 (ko)
JP (1) JP3959431B2 (ko)
KR (1) KR100304155B1 (ko)
AT (1) ATE206622T1 (ko)
AU (1) AU676162B2 (ko)
CA (1) CA2100709C (ko)
DE (1) DE69330899T2 (ko)
DK (1) DK0585986T3 (ko)
ES (1) ES2165361T3 (ko)
FI (1) FI118676B (ko)
MX (1) MX9304499A (ko)
NO (1) NO312009B1 (ko)
NZ (1) NZ248235A (ko)
PT (1) PT585986E (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
ES2183904T3 (es) * 1996-11-15 2003-04-01 Euratom Metodo extracorporeo para el tratamiento de celulas sanguineas.
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
US5854968A (en) * 1997-06-09 1998-12-29 Arch Development Corporation Process and apparatus for the production of BI-213 cations
EP1073609A4 (en) * 1998-03-30 2002-08-28 Sloan Kettering Inst Cancer BISMUTH-213 GENERATOR AND USES THEREOF
US7736651B1 (en) 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
CA2333125C (en) * 1998-05-26 2009-12-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
ES2203856T3 (es) 1998-06-22 2004-04-16 European Community Metodo y aparato para la preparacion de bi-213 para uso terapeutico humano.
CA2374001A1 (en) * 1999-06-07 2000-12-14 Center For Molecular Medicine And Immunology Alpha or beta emitters attached to fragments in radioimmunotherapy
US6852296B2 (en) * 2001-06-22 2005-02-08 Pg Research Foundation Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
WO2004001767A1 (en) * 2002-06-21 2003-12-31 Lynntech, Inc. Ion exchange materials for use in a bi-213 generator
EP1479399A1 (en) * 2003-05-22 2004-11-24 European Atomic Energy Community (Euratom) Method of loading a radioelement generator with mother radionuclide
US20050105666A1 (en) * 2003-09-15 2005-05-19 Saed Mirzadeh Production of thorium-229
CA2768658C (en) 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
CN107690334A (zh) 2015-06-05 2018-02-13 万能药业股份有限公司 使用针对haah的抗体对癌症的放射成像和放射治疗
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) * 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) * 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB2122641B (en) * 1982-06-07 1986-08-06 Otto A Gansow Metal chelate conjugated monoclonal antibodies where in the metal is an emitter
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) * 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
IL87405A0 (en) * 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
US4833329A (en) * 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4871352A (en) * 1987-12-07 1989-10-03 Controlled Release Technologies, Inc. Self-regulated therapeutic agent delivery system and method
JPH0720989B2 (ja) * 1988-05-25 1995-03-08 アメリカ合衆国 大環状キレート化合物の抱合体と診断的テスト方法
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
ES2053196T3 (es) * 1989-06-19 1994-07-16 Akzo Nv Metodo para la produccion de un radioinmunoconjugado.
US5254328A (en) * 1989-07-12 1993-10-19 Mallinckrodt Medical, Inc. Method of preparing a radiodiagnostic comprising a gaseous radionuclide, as well as a radionuclide generator suitable for using said method
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) * 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
NO312009B1 (no) 2002-03-04
KR100304155B1 (ko) 2001-11-22
DK0585986T3 (da) 2002-01-14
CA2100709A1 (en) 1994-01-28
AU676162B2 (en) 1997-03-06
US6127527A (en) 2000-10-03
US5641471A (en) 1997-06-24
EP0585986B1 (en) 2001-10-10
FI933350A (fi) 1994-01-28
NO932687L (no) 1994-01-28
EP0585986A1 (en) 1994-03-09
JPH06157350A (ja) 1994-06-03
DE69330899T2 (de) 2002-04-25
PT585986E (pt) 2002-03-28
US5641471C1 (en) 2001-05-15
CA2100709C (en) 2004-03-16
ATE206622T1 (de) 2001-10-15
FI933350A0 (fi) 1993-07-26
ES2165361T3 (es) 2002-03-16
JP3959431B2 (ja) 2007-08-15
DE69330899D1 (de) 2001-11-15
FI118676B (fi) 2008-02-15
NO932687D0 (no) 1993-07-26
AU4215493A (en) 1994-02-03
MX9304499A (es) 1994-04-29
NZ248235A (en) 1995-04-27

Similar Documents

Publication Publication Date Title
KR940005295A (ko) 부위- 지향성 치료방법 및 치료수단
Order et al. Use of isotopic immunoglobulin in therapy
NZ217570A (en) Antibody complexes of hapten modified diagnostic or therapeutic agents
ATE58297T1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
ATE242635T1 (de) Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren
UA49799C2 (uk) Циклопептиди, спосіб їх одержання, фармацевтична композиція, що їх містить, спосіб її одержання, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів
BG102657A (en) Method for radiation retention by means of fullerene molecules
Dahle et al. Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy
NL7600104A (nl) Dragermateriaal voor plaatsbepaling met radio-ak- tieve isotopen in medisch onderzoek en werkwijze voor de bereiding daarvan.
SE8402098D0 (sv) Perfluorkarbonemulsion, framstellning derav samt dess anvendning i terapi
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
HUT51594A (en) Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody
Rubens Antibodies as carriers of anticancer agents
DK0730871T3 (da) Radioaktivt kompleks og anvendelsen heraf til strålebehandling
US20080279772A1 (en) Methods for detecting pathological sites
Roberts et al. Labeling antibodies with copper radionuclides using N-4-nitrobenzyl-5-(4-carboxyphenyl)-10, 15, 20-tris (4-sulfophenyl) porphine
Anderson et al. Antibodies labeled with 199Au: Potential of 199Au for radioimmunotherapy
JP2016520650A (ja) スズ−１１７ｍでの免疫性、炎症性及び変形性関節炎の治療
GR880100589A (en) Metalloporfyrines for the inversion of the toxic activity for the tumors treatment
CN108472556B (zh) 同位素制备方法
DE3689299D1 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
Allen et al. Evaluation of N-Succinimidyl S-Acetylthioacetate Ligand for Radiolabeling of Humanized Antibodies with 188Rhenium
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
Lion et al. INTERNAL RADIOPROTECTION AND ELECTRON DELOCALIZATION.
Laster et al. In vivo studies in NCT with a boronated porphyrin and tumor growth delay as an end point

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130628

Year of fee payment: 13

EXPY Expiration of term